CEO of Dr Reddy’s Laboratories, Erez Israeli believes his company’s affordable medicines benefit the U.S. market and will be supported by the Trump administration. A strong U.S. dollar is bolstering earnings growth. He expects continued double-digit growth in the coming year with no significant competition in the pharma landscape.